



## Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 25, 2026


- Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical and preclinical programs advancing with defined milestones
- Achieved fifth program milestone with Sanofi, totaling \$134 million in payments to date; five Recursion discovery program packages have been accepted to date, establishing a growing joint portfolio of novel AI-driven small molecules for immunology and oncology
- \$754 million of cash and cash equivalents; exceeded original cost savings guidance and now expect runway into early 2028 without additional financing, reflecting disciplined capital allocation alongside continued platform and program investment

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXXR) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its fourth quarter and full year ending December 31, 2025.

Recursion will host an Earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT from Recursion's [X](#), [LinkedIn](#), and [YouTube](#) accounts giving analysts, investors, and the public the opportunity to ask questions of the Company by submitting questions here: <https://forms.gle/TQ4vgUTLKsFmiku6>.

"Recursion has reached an inflection point: moving from proving that AI can participate in drug discovery to demonstrating that an AI-native operating system can generate clinical proof and durable value," said Najat Khan, Ph.D., CEO & President of Recursion. "Our first AI-enabled clinical proof of concept in FAP and our fifth program milestone achieved with Sanofi reflect the increasing maturity of a deeply integrated model — one that connects biology, chemistry, and clinical development into a continuous learning system. We enter 2026 with five differentiated clinical programs advancing with defined next-stage milestones, a growing discovery portfolio informed by proprietary platform insights, and more than \$500 million in upfront and progress-based milestone payments earned to date. Pairing bold ambition with disciplined execution, we are building Recursion to compound over time — translating insight into molecules, molecules into medicines, and innovation into measurable impact for patients and shareholders alike."

**Summary of Business Highlights: Driving a diversified pipeline powered by the end-to-end AI-native Recursion OS - wholly-owned and partnered programs**



1. Includes preclinical programs that are expected to enter the clinic within the next 18 months  
 2. Milestones: Potential Roche and Genentech and Sanofi milestones per small molecule program. Royalties: Recursion is eligible for tiered royalties up to high single digits (Roche and Genentech) and up to double digits (Sanofi)

**2025 Wholly Owned Pipeline Achievements: Advancing programs with strong therapeutic rationale, powered by the Recursion OS**

	Target	Disease Indication	Late Discovery	Preclinical	Phase 1/2	Phase 3	Potential Milestone
<b>REC-4881</b>	MEK1/2	Familial adenomatous polyposis (FAP)					Initiate FDA engagement - 1H26
<b>REC-617</b>	CDK7	Advanced solid tumors					Combination data - 1H27
<b>REC-1245</b>	RBM39	Biomarker-enriched solid tumors & lymphoma					Ph 1/2 data - 1H26
<b>REC-3565</b>	MALT1	B-cell malignancies					Ph 1 data - 1H27
<b>REC-4539</b>	LSD1	Solid tumors & hematology oncology					Ph 1 trial start - 1H26
<b>REC-7735</b>	PI3Kα H1047R	Solid tumors (incl. HR+ breast cancer)					Go/no-go decision - 2H26 <sup>1</sup>
<b>REC-102</b>	ENPP1	Hypophosphatasia (HPP)					Go/no-go decision - 2H26 <sup>1</sup>

- REC-4881 (MEK1/2):** Provided the first clinical validation of the Recursion OS from a novel phenotypic insight, with [positive preliminary efficacy results from the ongoing Phase 2](#) portion of the TUPELO study in FAP, a disease with no approved pharmacotherapies.
  - REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12).
  - After 12 weeks off therapy (week 25 of the study), 82% of evaluable patients (9 of 11) maintained a durable reduction in total polyp burden, with a 53% median reduction observed from baseline.
  - REC-4881 (4 mg QD) has a safety profile consistent with MEK1/2 inhibition, with the majority of treatment-related adverse events being Grade 1 or 2, Grade 3 events occurring in 15.8% of the safety-evaluable patients, and no Grade ≥4 TRAEs reported to date. The most frequent TRAEs (at ≥10%) included dermatitis acneiform / rash and blood CPK increase.
- REC-617 (CDK7):** A potential best-in-class CDK7 inhibitor optimized for improved therapeutic index using our AI-driven precision design platform and identified as lead candidate in under 11 months with 136 novel compounds synthesized, delivered further Phase 1/2 results in November 2025, demonstrating promising safety and preliminary efficacy signals. The program is currently advancing in ongoing Phase 1 combination studies in 2L+ platinum-resistant ovarian cancer (PROC) alongside Phase 2 monotherapy expansion.
- REC-7735 (PI3Kα H1047R):** Recursion announced new preclinical efficacy data on REC-7735, a potential best-in-class PI3Kα H1047R inhibitor, precision designed with 242 compounds synthesized from first novel hit to REC-7735 in 10 months using the Recursion OS platform. Current pan-PI3Kα inhibitors lack selectivity over the wild-type protein, resulting in metabolic liabilities, including hyperglycemia, that often necessitate dose reductions in a significant portion of non diabetic patients and the exclusion entirely of diabetic patients from treatment. REC-7735 demonstrates >100-fold selectivity for the H1047R mutation over WT PI3Kα suggesting potential improved tolerability and is currently in IND-enabling studies.

**Expected upcoming milestones across Recursion's wholly-owned pipeline:**

- REC-1245 (RBM39): Early Phase 1 safety and PK monotherapy data expected in 1H26
- REC-4881 (MEK1/2):
  - Initiate FDA engagement in 1H26 to align on a potential registration pathway for REC-4881, alongside ongoing dosing optimization and expansion of TUPELO to include patients aged 18+ to support a broader development strategy
  - Additional Phase 1b/2 clinical data expected in 1H27
- REC-7735 (PI3Kα H1047R) and REC-102 (ENPP1): IND-enabling studies ongoing; data-driven go/no-go decision on Phase 1 initiation expected in 2H26
- REC-617 (CDK7): Early Phase 1 safety and PK combination data expected in 1H27
- REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27
- REC-4539 (LSD1): Early Phase 1 safety and PK monotherapy data expected in 2H27

## Advancing partnered discovery, with over \$500 million in milestone payments achieved to date:


- **Sanofi:**
  - **Advancing Programs for Complex Targets:** Recursion is using its platform to discover, design, and advance a joint portfolio of 5+ AI-driven novel small molecule programs across immunology and oncology. Recursion continues to design against challenging and diverse protein targets.
  - The collaboration has the potential for up to 15 AI-designed small molecule programs.
  - **Milestone Payments:** Recursion has now received \$134 million in upfront and progress-based milestones from this partnership to date.
    - In the next 12-18 months, there is potential for additional near-term milestones as the first programs advance towards development candidates and earlier-stage programs progress.
  - **Fifth Progress-based Milestone:** In February 2026, Recursion achieved its fifth milestone across the collaboration, generating a \$4M payment from Sanofi. This 5th milestone reflects a first-in-class Sanofi-partnered oncology program against a historically difficult and novel biological space.
    - Recursion's AI-driven design coupled with Recursion's physics-based capabilities has produced selective, orally active lead series.
- **Roche and Genentech:**
  - **Neuron Map:** In partnership with Roche and Genentech, Recursion built the first whole-genome CRISPR knockout map generated from a subset of 1 trillion internally manufactured iPSC-derived neuronal cells (\$30 million milestone payment, accepted in 2024). This proprietary dataset is being used in partnership with Roche and Genentech to identify potential new targets in neuroscience, a field which has historically suffered from limited new discoveries.
  - **Microglia Map:** Recursion built and Roche and Genentech accepted a second neuroscience Phenomap, a first-of-its-kind whole-genome CRISPR knockout map generated from over 100 billion internally manufactured iPSC-derived microglial cells (\$30 million milestone payment, accepted in 2025). With approximately 46 million images, the scale and quality of this proprietary map enables us, in partnership with Roche and Genentech, to leverage the power of AI to explore novel targets and pathways.
  - **Gastrointestinal-Oncology Advancements:** We have built four proprietary Phenomaps which are being leveraged under the collaboration to identify novel insights that can be used to initiate programs for a gastrointestinal-oncology indication including continuing to advance one program optioned by Roche and Genentech.
  - **Milestones and Collaboration:** In total, Recursion has received \$213 million in upfront and milestone payments from the collaboration. Roche and Genentech have accepted 6 Phenomaps and initiated one small molecule program based on Phenomap insights to date. The companies have also identified a number of biological insights from Phenomaps that are now being validated or advanced as potential novel targets.

## Meaningful potential upcoming milestones across partnered discovery:

- Sanofi programs continue advancing towards potential lead series and development candidate designation milestones in the next 12-18 months.
- The Company expects to translate biological insights from maps delivered to Roche and Genentech to early stage programs across 2026 and beyond.

## 2025 Recursion OS Advances: Driving platform innovations, grounded in impact

**Full Stack AI-powered Platform:** The Recursion Operating System (OS) is continuing to drive program development by integrating AI across multimodal biology, precision design, and next-generation clinical development—enabling faster, more efficient, and more innovative drug discovery and development from biology to insight, insight to molecule, and molecule to patient.



- **Biology to Insight:** Initiating programs with deep biological grounding
  - *Unmatched multimodal scale:* At-scale cellular imaging, integrated with proprietary and partner omics datasets, has

created one of the most comprehensive and reliable biological datasets in biopharma.

- *From signal to selection*: This foundation enables systematic discovery of novel biology — rapidly triaging hundreds of signals into dozens of targets for experimental validation within weeks.
- **Insight to Molecule**: Designing differentiated molecules more efficiently
  - *Proven platform productivity and reproducibility*: To date, the platform has delivered >10 development candidates that address a wide variety of previously unsolved biology or chemistry problems.
  - Advanced candidates have been delivered by synthesizing ~330 compounds per program in ~17 months, compared to industry averages of over 2,500 compounds and 42 months, respectively.
  - Leverages an AI-native engine for the industrialized generation of over 100 million molecules annually through synthetically aware design, generating novel and patentable compounds.
- **Molecule to Patient**: Advancing medicines into the clinic with improved patient relevance
  - *Integrated high-quality, linked patient datasets to strengthen programs, bolster preclinical and early clinical data to select patients and optimize recruitment*: Contextualized the single-arm efficacy of REC-4881 in the TUPELO study through real-world evidence analytics and AI-enabled data extraction, to build a comprehensive view of the lived, progressive-disease FAP patient experience, to directly inform clinical development strategy.
  - *Rapid, data-driven optimization of clinical trial operations*: Deployed global clinical trial site intelligence database, covering a wide swath of historical clinical trials, to reduce trial country and site selection from months to hours.

#### Integration initiatives completed with continued disciplined capital management

Several operating initiatives were completed through the course of 2025 focused on integration of the Exscientia combination and the prioritization of high impact investments in the pipeline and platform. These initiatives allowed Recursion to achieve a cash operating expense of approximately \$400 million, approximately 10% lower than guidance for 2025. The company will continue to apply a rapid, data-driven investment strategy to continue efficiently growing its differentiated pipeline and leading platform. Management expects 2026 cash operating expense, excluding partnership inflows and transaction costs, to be less than \$390 million.

#### Fourth quarter and full year 2025 financial results

- **Cash Position**: Cash, cash equivalents and restricted cash were \$753.9 million as of December 31, 2025 compared to \$603.0 million as of December 31, 2024. Based on current operating plans and with no additional financing, the Company's expected cash runway extends into early 2028.
- **Revenue**: Total revenue, consisting primarily of revenue from collaboration agreements, was \$35.5 million for the fourth quarter of 2025, compared to \$4.5 million for the fourth quarter of 2024. Total revenue, consisting primarily of revenue from collaboration agreements, was \$74.7 million for the year ended December 31, 2025, compared to \$58.8 million for the year ended December 31, 2024. The quarter over quarter increase was driven by the timing of achievement of a \$30 million milestone payment for the second phenomap from Roche and Genentech in October 2025 for which the Company recognized a portion as revenue in the fourth quarter of 2025, in addition to an increase in revenue relating to the Company's collaboration with Sanofi. The year over year change was primarily due to the inclusion of Exscientia's results for the full year of 2025.
- **Research and Development Expenses**: Research and development expenses were \$95.9 million for the fourth quarter of 2025, compared to \$98.3 million for the fourth quarter of 2024. Research and development expenses were \$475.3 million for the year ended December 31, 2025, compared to \$314.4 million for the year ended December 31, 2024. The quarter over quarter decrease compared to the prior period was primarily driven by improved operating efficiency and a strategic reprioritization of our clinical portfolio in the second quarter of 2025. The increase in 2025 research and development expenses compared to the prior year was driven by Tempus record purchases of \$49.9 million, acquired IPR&D purchases of \$22.8 million and the inclusion of Exscientia's results for the full year of 2025.
- **General and Administrative Expenses**: General and administrative expenses were \$33.7 million for the fourth quarter of 2025 compared to \$77.2 million for the fourth quarter of 2024. General and administrative expenses were \$176.6 million for the year ended December 31, 2025, compared to \$178.2 million for the year ended December 31, 2024. The decrease compared to the prior period was primarily due to the inclusion of transaction expenses from the business combination with Exscientia in the fourth quarter of 2024. The decrease in 2025 general and administrative expenses compared to the prior year was driven by the inclusion of Exscientia's results for the full year of 2025.
- **Net Loss**: Net loss was \$108.1 million for the fourth quarter of 2025, compared to a net loss of \$178.9 million for the fourth quarter of 2024. Net loss was \$644.8 million for the year ended December 31, 2025, compared to a net loss of \$463.7 million for the year ended December 31, 2024.
- **Operational Cash Flows**: Net cash used in operating activities was \$46.1 million for the fourth quarter of 2025, compared to net cash used in operating activities of \$115.4 million for the fourth quarter of 2024. Net cash used in operating activities

was \$371.8 million for the year ended December 31, 2025, compared to net cash used in operating activities of \$359.2 million for the year ended December 31, 2024. The quarter over quarter decrease in cash used was primarily driven by the receipt of the Roche \$30 million milestone, four quarter 2024 spend on the Exscientia transaction and 2025 operational efficiencies due to our various strategic initiatives. The increase in cash used in operating activities year over year was primarily driven by the inclusion of Exscientia's operations, for which the business combination with Recursion closed in November 2024.

- **Cash Operating Expense:** Cash operating expense, excluding partnership inflows and transaction costs, for the year ended December 31, 2025 was \$399.2 million.

#### About Recursion

Recursion (NASDAQ: RXX) is a clinical stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its wholly owned and partnered pipeline in oncology, rare disease, neuroscience, immunology, and other therapeutic areas with significant unmet need. Enabling its mission is the Recursion OS, an AI-native, end-to-end drug discovery and development platform integrating biology, chemistry, and clinical development into a unified intelligence system. Powered by proprietary multimodal data, purpose-built AI models, and bilingual teams fluent in both science and AI, the Recursion OS is designed to translate complex science into medicines that matter — faster, better, and at scale — for patients who are waiting.

Recursion's platform infrastructure is anchored in Salt Lake City, Utah and Milton Park, Oxfordshire, where its automated biology and chemistry laboratories generate proprietary data at industrial scale. Recursion also maintains offices in New York, Montréal, and London, three global hubs for talent and leadership at the intersection of AI and scientific innovation. Learn more at [www.recursion.com](http://www.recursion.com), or connect on [X](#) and [LinkedIn](#).

#### Media Contact

[media@recursion.com](mailto:media@recursion.com)

#### Investor Contact

[investor@recursion.com](mailto:investor@recursion.com)

**Recursion Pharmaceuticals Inc**  
**Consolidated Statements of Operations (unaudited)**  
*(in thousands, except share and per share amounts)*

	Three months ended December 31,		Years ended December 31,	
	2025	2024	2025	2024
<b>Revenue</b>				
Operating revenue	\$ 35,351	\$ 4,511	\$ 74,256	\$ 58,488
Grant revenue	186	35	425	351
<b>Total revenue</b>	<b>35,537</b>	<b>4,546</b>	<b>74,681</b>	<b>58,839</b>
<b>Operating costs and expenses</b>				
Cost of revenue	14,276	12,794	70,953	45,238
Research and development	95,940	98,333	475,271	314,421
General and administrative	33,656	77,186	176,589	178,184
<b>Total operating costs and expenses</b>	<b>143,872</b>	<b>188,313</b>	<b>722,813</b>	<b>537,843</b>
<b>Loss from operations</b>	<b>(108,335)</b>	<b>(183,767)</b>	<b>(648,132)</b>	<b>(479,004)</b>
Other income, net	231	4,869	3,237	14,216
<b>Loss before income tax benefit</b>	<b>(108,104)</b>	<b>(178,898)</b>	<b>(644,895)</b>	<b>(464,788)</b>
Income tax benefit (expense)	(20)	(7)	136	1,127
<b>Net loss</b>	<b>\$ (108,124)</b>	<b>\$ (178,905)</b>	<b>\$ (644,759)</b>	<b>\$ (463,661)</b>
<b>Per share data</b>				
<b>Net loss per share of Class A, B and Exchangeable common stock, basic and diluted</b>	<b>\$ (0.21)</b>	<b>\$ (0.53)</b>	<b>\$ (1.44)</b>	<b>\$ (1.69)</b>
<b>Weighted-average shares (Class A, B and Exchangeable) outstanding, basic and diluted</b>	<b>526,719,743</b>	<b>336,035,980</b>	<b>447,446,109</b>	<b>274,207,146</b>

**Recursion Pharmaceuticals Inc**  
**Consolidated Balance Sheets (unaudited)**  
*(in thousands)*

	<u>December 31,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>
<b>Assets</b>		
<b>Current assets</b>		
Cash and cash equivalents	\$ 743,294	\$ 594,350
Restricted cash	4,594	3,045
Other receivables	24,649	49,166
Prepaid data assets	11,742	29,601
Other current assets	28,566	38,107
<b>Total current assets</b>	<b>812,845</b>	<b>714,269</b>
Restricted cash, non-current	6,033	5,629
Property and equipment, net	103,931	141,063
Operating lease right-of-use assets	45,339	65,877
Financing lease right-of-use assets	20,210	26,273
Intangible assets, net	309,903	335,855
Goodwill	162,158	148,873
Deferred tax assets	957	1,934
Other assets, non-current	12,754	8,825
<b>Total assets</b>	<b>\$ 1,474,130</b>	<b>\$ 1,448,598</b>
<b>Liabilities and stockholders' equity</b>		
<b>Current liabilities</b>		
Accounts payable	\$ 18,118	\$ 21,613
Accrued expenses and other liabilities	70,230	81,872
Unearned revenue	37,605	61,767
Operating lease liabilities	12,663	13,795
Notes payable and financing lease liabilities	9,091	8,425
<b>Total current liabilities</b>	<b>147,707</b>	<b>187,472</b>
Unearned revenue, non-current	114,012	118,765
Operating lease liabilities, non-current	46,647	67,250
Notes payable and financing lease liabilities, non-current	9,564	19,022
Deferred tax liabilities	23,255	16,575
Other liabilities, non-current	2,080	4,732
<b>Total liabilities</b>	<b>343,265</b>	<b>413,816</b>
<b>Stockholders' equity</b>		
Common stock (Class A, B and Exchangeable)	5	4
Additional paid-in capital	3,170,145	2,473,698
Accumulated deficit	(2,076,002)	(1,431,283)
Accumulated other comprehensive income (loss)	36,717	(7,637)
<b>Total stockholders' equity</b>	<b>1,130,865</b>	<b>1,034,782</b>
<b>Total liabilities and stockholders' equity</b>	<b>\$ 1,474,130</b>	<b>\$ 1,448,598</b>

**Recursion Pharmaceuticals Inc**  
**Selected Cash Flow Information (unaudited)**  
*(in thousands)*

	<b>Three months ended December 31,</b>		<b>Years ended December 31,</b>	
	<b>2025</b>	<b>2024</b>	<b>2025</b>	<b>2024</b>
Net cash used in operating activities	\$ (46,073)	\$ (115,430)	\$ (371,808)	\$ (359,174)
Net cash provided by (used in) investing activities	(1,244)	275,456	(16,871)	260,059
Net cash provided by financing activities	132,006	10,639	521,532	304,120
Effect of exchange rate changes on cash, cash equivalents and restricted cash	2,087	(3,472)	18,044	(3,406)
Cash, cash equivalents and restricted cash, beginning of period	667,145	435,831	603,024	401,425

Cash, cash equivalents and restricted cash, end of period	\$	753,921	\$	603,024	\$	753,921	\$	603,024
---	----	---------	----	---------	----	---------	----	---------

### Non-GAAP Financial Measure

The reconciliation of cash operating expense to net cash used in operating activities is provided in the following table:

<b>Cash operating expense - 2025</b>	<b>(in millions)</b>
Net cash used in operating activities	\$ 371.8 *
Add: partnership inflows	37.0
Subtract: transaction costs	(9.6)
<b>Cash operating expense - 2025</b>	<b>\$ 399.2</b>

\*This is from the Recursion inc Consolidated Statement of Cash Flows for the year ended December 31, 2025 (see above)

To supplement our financial statements prepared in accordance with U.S. GAAP, we monitor and consider cash operating expense, which is a non-GAAP financial measure. We define cash operating expense as the net cash used in operating activities, excluding non-ordinary course transaction costs and partnership cash inflows. This non-GAAP financial measure is not based on any standardized methodology prescribed by U.S. GAAP and is not necessarily comparable to similarly-titled measures presented by other companies. We believe cash operating expense to be a liquidity measure that provides useful information to management and investors about the amount of cash consumed by the operations of the business. A limitation of using this non-U.S. GAAP measure is that cash operating expense does not represent the total change in cash and cash equivalents for the period because it excludes cash provided by or used for other investing and financing activities. We account for this limitation by providing information about our capital expenditures and other investing and financing activities in the statements of cash flows in our financial statements. Additionally, we reconciled cash operating expense above to net cash used in operating activities, the most directly comparable U.S. GAAP financial measure. In addition, it is important to note that other companies, including companies in our industry, may not use cash operating expense, may calculate cash operating expense in a different manner than we do or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of cash operating expense as a comparative measure. Because of these limitations, cash operating expense should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with U.S. GAAP.

### Forward-Looking Statements

This document contains information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the impact of the acceptance of the fifth milestone by Sanofi on future developments and potential treatments; the impact of FAP trial on the Recursion OS and other clinical and preclinical programs; financial position, cash runway, and ability to reduce our cash expense; Recursion's ability to translate platform insights into tangible proof; Recursion's ability to discover and develop medicines and the occurrence or realization of near-term milestones; the timing of data readouts and other milestones; the impact of preclinical data on trial outcomes; Recursion's future as a leader in TechBio and ability to deliver better treatments to patients faster; expectations relating to early and late stage discovery, preclinical, and clinical programs, including timelines for commencement of and enrollment in studies, data readouts, meetings with regulators, and progression toward IND-enabling studies; expectations and developments with respect to licenses and collaborations, including option exercises by partners and the amount and timing of potential milestone payments, and the acceleration of progress across multiple partnered programs; prospective products and their potential future indications and market opportunities; developments with Recursion OS, including achieving future returns on investment in the platform and the ability to discover and develop new medicines and provide insights into patient populations; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as "plan," "will," "expect," "anticipate," "intend," "believe," "potential," "continue," and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K. All forward-looking statements are based on management's current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

Photos accompanying this announcement are available at

<https://www.globenewswire.com/NewsRoom/AttachmentNg/390d5476-6bac-4d2c-bb88-73ae897d031f>


<https://www.globenewswire.com/NewsRoom/AttachmentNg/ac407502-56fa-45c8-acd1-2224ba7e7b91>

<https://www.globenewswire.com/NewsRoom/AttachmentNg/90f273e3-ec42-4a1b-b026-d58d60a3b338>



Source: Recursion Pharmaceuticals

Recursion OS: An AI-native, full stack platform for drug discovery and clinical development



## Recursion Pharmaceuticals

### Recursion's wholly owned pipeline: Translating insight into proof

Target	Disease Indication	Lead Discovery	Preclinical	Phase 1/2	Phase 3	Potential Milestones
REC-4881	WNT/PCP Familial adenomatous polyposis (FAP)	✓	✓	✓		Initial FDA engagement - 2025
REC-417	CDK7 Advanced solid tumors	✓	✓	✓		Combination data - 2027
REC-0345	SPK309 Somatostatin-receptor-expressing solid tumors & lymphomas	✓	✓	✓		Phase 1/2 data - 2026
REC-0866	HR231 Breast malignancies	✓	✓	✓		Phase 1 data - 2027
REC-4828	USP10 Solid tumors & hematologic oncology	✓	✓	✓		Phase 1/2 data - 2026
REC-7726	PCSK9 Solid tumors (incl. BRCA) (Breast cancer)	✓	✓	✓		Combination studies - 2027
REC-082	SNRP1 Hemophagocytosis (HPS)	✓	✓	✓		Combination studies - 2027

## Recursion Pharmaceuticals

### Recursion's progress, by the numbers



## Recursion Pharmaceuticals